Company profilePharmaceutical#564 of 1,318 in Pakistan✓ No DRAP alerts

Filix Pharmaceuticals Pvt Ltd

Pharmaceutical company · 22 brands · 23 molecules

Ranked #18 of 24 companies in Allergy

22 registered products 17 pharmaceutical brands 23 distinct molecules 0 DRAP alerts

Company overview

22
registered products
17
pharmaceutical brands
23
distinct molecules
3
therapeutic classes
0
DRAP alerts

Filix Pharmaceuticals Pvt Ltd is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 22 product registrations across 23 distinct molecules. Its portfolio is concentrated in Allergy and Skin Conditions. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Filix

14 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Skin Conditions 1
Anti-Infectives 1

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

13
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
202513

Top molecules by brand count

Levofloxacin2 brands
Isotretinoin2 brands
Moxifloxacin2 brands
Omeprazole2 brands
Ciprofloxacin ...... 500 Mg1 brand
Ciprofloxacin ...... 250 Mg1 brand
Isotretinoin ...... 20 Mg1 brand
Levofloxacin .........................500Mg1 brand

Therapeutic classes

Allergy · 1Skin Conditions · 1Anti-Infectives · 1

Conditions treated

Conventional Agents · 1Acne/Oral · 1General Infections · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official24 products · Rs 201.25 – Rs 941.24
Servaid3 products · Rs 133.4 – Rs 608
Median across source: Rs 475

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

BIO LABS (PVT) LTD.12 shared molecules
EPHARM LABORATORIES12 shared molecules
PEARL PHARMACEUTICALS11 shared molecules
HIGH - Q INTERNATIONAL11 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

GENOME PHARMACEUTICALS (PVT) LTD holds 104 molecules not in this portfolio
AcitretinAmlodipineAnastrazoleAnastrozoleAprepitantArtesunate
SEMOS PHARMACEUTICALS (PVT) LTD. holds 51 molecules not in this portfolio
AmodiaquineAmodiaquine 150MgArtesunateAscorbic AcidBisacodylBuprenorphine
Horizon Pharmaceuticals (Pvt) Limited holds 129 molecules not in this portfolio
000 I.UAcyclovirAlbendazoleAmlodipineAmoxicillinAmoxycillin Base

Get the full profile for Filix

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.